NEW YORK, NY / ACCESSWIRE / October 12, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alnylam Pharmaceuticals, Inc. ("Alnylam" or "the Company") (NASDAQ:ALNY). Investors who purchased Alnylam securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/alny.
The investigation concerns whether Alnylam has violated federal securities laws.
Investigation Details:
On October 9, 2023, Alnylam issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) in response to the Company's supplemental New Drug Application (sNDA) for patisiran for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis." Alnylam announced that "[t]he CRL indicated that the clinical meaningfulness of patisiran's treatment effects for the cardiomyopathy of ATTR amyloidosis had not been established, and therefore, the sNDA for patisiran could not be approved in its present form" and that "[a]s a result of the CRL, the Company will no longer pursue an expanded indication for patisiran in the U.S." On this news, Alnylam's stock price fell sharply during intraday trading on October 9, 2023.
What's Next?
If you are aware of any facts relating to this investigation or purchased Alnylam securities, you can assist this investigation by visiting the firm's site: bgandg.com/alny . You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View source version on accesswire.com:
https://www.accesswire.com/791747/alnylam-pharmaceuticals-inc-alny-investigation-bronstein-gewirtz-grossman-llc-encourages-investors-to-seek-compensation-for-alleged-wrongdoings
